Dominique L Braun Selected Research

Hepatitis C

11/2022	Sustained Effect on Hepatitis C Elimination Among Men Who Have Sex With Men in the Swiss HIV Cohort Study: A Systematic Re-Screening for Hepatitis C RNA Two Years Following a Nation-Wide Elimination Program.
1/2015	A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dominique L Braun Research Topics

Disease

27	Infections 03/2024 - 01/2015
6	COVID-19 02/2024 - 08/2021
6	HIV Infections (HIV Infection) 01/2023 - 11/2014
3	Persistent Infection 10/2023 - 10/2019
2	Weight Gain 04/2024 - 11/2021
2	Body Weight (Weight, Body) 04/2024 - 11/2022
2	Viremia 03/2024 - 01/2022
2	Hepatitis C 11/2022 - 01/2015
2	Hypertension (High Blood Pressure) 01/2022 - 11/2021
2	Syphilis 01/2019 - 01/2017
1	Herpes Zoster 03/2024
1	Neuralgia (Stump Neuralgia) 03/2024
1	Neoplasms (Cancer) 07/2023
1	Dyslipidemias (Dyslipidemia) 01/2023
1	Genetic Risk Score 01/2023
1	Inflammation (Inflammations) 11/2022
1	Type 2 Diabetes Mellitus (MODY) 11/2022
1	Insulin Resistance 11/2021
1	Acquired Immunodeficiency Syndrome (AIDS) 11/2021
1	Opportunistic Infections (Opportunistic Infection) 01/2020
1	Chronic Hepatitis C 01/2018
1	Hepatitis B 08/2016
1	Fibrosis (Cirrhosis) 01/2015
1	Coinfection 01/2015
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2015
1	Acute Retroviral Syndrome 01/2014
1	Disease Progression 01/2014

Drug/Important Bio-Agent (IBA)

7	RNA (Ribonucleic Acid)IBA 03/2024 - 01/2019
5	DNA (Deoxyribonucleic Acid)IBA 03/2024 - 08/2016
4	AntibodiesIBA 01/2024 - 08/2016
4	AntigensIBA 07/2023 - 01/2018
4	Broadly Neutralizing AntibodiesIBA 01/2022 - 11/2016
3	Antiviral Agents (Antivirals)IBA 02/2024 - 01/2018
3	dolutegravirIBA 10/2023 - 10/2019
2	tenofovir alafenamideIBA 04/2024 - 11/2021
2	LipidsIBA 04/2024 - 01/2019
2	VaccinesIBA 10/2023 - 01/2022
2	InterferonsIBA 07/2023 - 01/2018
2	Protease Inhibitors (Protease Inhibitor)IBA 01/2022 - 01/2015
2	NucleotidesIBA 01/2019 - 11/2014
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2017 - 08/2016
1	CytokinesIBA 07/2023
1	A-Form DNA (A-DNA)IBA 01/2023
1	abacavir (Ziagen)FDA Link 01/2023
1	canakinumab FDA Link 11/2022
1	Moxifloxacin (Avelox)FDA Link 06/2022
1	MacrolidesIBA 06/2022
1	NucleosidesIBA 01/2022
1	remdesivirIBA 01/2022
1	ensovibepIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Staphylococcal Protein A (Protein A)IBA 01/2022
1	Reverse Transcriptase InhibitorsIBA 01/2022
1	IntegrasesIBA 01/2022
1	Integrase InhibitorsIBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	Raltegravir Potassium FDA Link 11/2021
1	EnzymesIBA 01/2019
1	grazoprevirIBA 01/2019
1	elbasvirIBA 01/2019
1	Immunoglobulin G (IgG)IBA 01/2018
1	Nevirapine (Viramune)FDA Link 01/2017
1	Viral AntigensIBA 11/2016
1	Silybin (Lagosa)IBA 01/2015
1	Ribavirin (Virazole)FDA LinkGeneric 01/2015
1	Biomarkers (Surrogate Marker)IBA 01/2014

Therapy/Procedure

9	Art Therapy 04/2024 - 01/2020
8	Therapeutics 02/2024 - 01/2015
2	Highly Active Antiretroviral Therapy (HAART) 10/2023 - 10/2019
1	Drug Therapy (Chemotherapy) 10/2023